Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy

Liver International

Volumn 38, Issue 1, 2018, Pages 6-14

  Tujios, Shannan R ^a   Lee, William M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

acute liver failure; drug induced liver injury; hepatotoxicity; idiosyncratic

Indexed keywords

ACETYLCYSTEINE; ANESTHETIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE INHIBITOR; PSYCHOTROPIC AGENT;

ACUTE LIVER FAILURE; ALTERNATIVE MEDICINE; CLINICAL OUTCOME; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; INTENSIVE CARE; LIVER BIOPSY; LIVER TRANSPLANTATION; PATHOGENESIS; PROGNOSIS; REVIEW; TOXIC HEPATITIS; CHEMICALLY INDUCED; MORTALITY; PREDICTIVE VALUE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; LIVER FAILURE, ACUTE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 85038835803     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13535     Document Type: Review

References (58)

1. Reuben A, Koch DG, Lee WM, The Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2010;52:2065-2078.
2. Escorsell A, Mas A, de la Mata M, Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl. 2007;13:1389-1395.
3. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102:2459-2463.
4. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (Paracetamol)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15:398-405.
5. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451-455.
6. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterol. 2013;144:1419-1425.
7. Suk KT, Kim JD, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012;107:1380-1387.
8. Larson AM, Fontana RJ, Davern TJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42:1367-1372.
9. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis. 2014;34:123-133.
10. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340-1352.
11. Koch DG, Speiser JL, Durkalski V, et al. The natural history of severe acute liver injury. Am J Gastroenterol Advance Online Publication. 2017. https://doi.org/10.1038/ajg.2017.98.
12. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323.
13. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117-2126.
14. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463-470.
15. Bjornsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63:590-603.
16. Ganger D, Rule JA, Bass NM, et al. Solving indeterminate etiology in acute liver failure: the contribution of expert opinion to the process of causality adjudication. Hepatology. 2016;64(Suppl. 51):52.
17. Temple R. Hy's Law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15:241-243.
18. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512-521.
19. Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147:96-108.
20. Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147:109-118.
21. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661-670.
22. Lefkowitch JH. The pathology of acute liver failure. Adv Anat Pathol. 2016;23:144-158.
23. Mosedale M, Watkins P. Drug-induced liver injury: advances in mechanistic understanding that will inform future risk management. Clin Pharm Therapeut. 2017.
24. Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 2014;34:367-378.
25. Metushi IG, Sanders C, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology. 2014;59:1084-1093.
26. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genetics. 2010;42:711-714.
27. Nicoletti P, Aithal GP, Bjornsson ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152:1078-1089.
28. Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007;27:465-474.
29. Zhao P, Wang C, Liu W, et al. Causes and outcomes of acute liver failure in China. Avila MA, ed. PLoS ONE. 2013;8:e80991.
30. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis. 2009;29:372-382.
31. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury form herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60:399-408.
32. Hillman L, Gottfried M, Whitsett M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016;111:958-965.
33. Fong TL, Klontz KC, Canas-Coto A, et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol. 2010;105:1561-1566.
34. Heidemann LA, Navarro VJ, Ahmad J, et al. Severe acute hepatocellular injury attributed to OxyELITE Pro: a case series. Dig Dis Sci. 2016;61:2741-2748.
35. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015;41:116-125.
36. Yuan L, Kaplowitz N. Mechanisms of drug-induced liver injury. Clin Liver Dis. 2013;17:507-518.
37. Reddy KR, Ellerbe C, Schilsky M, et al. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the US. Liver Transpl. 2015;22:505-515.
38. Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011;9:517-523.
39. LiverTox.nih.gov. Available from https://livertox.nlm.nih.gov//Halothane.htm. Accessed June 10, 2017.
40. Chalasani N, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950-966.
41. ™. Drug Saf. 2010;33:503-522.
42. Hadem J, Tacke F, Bruns T, et al. Etiologies and outcomes of acute liver failure in Germany. Clin Gastroenterol Hepatol. 2012;10:664-669.
43. Hernández N, Bessone F, Sánchez A, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol. 2014;13:231-239.
44. Kumar R, Shalimar, Bhatia V, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665-1674.
45. Devarbhavi H, Singh R, Patil M, et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28:161-167.
46. de Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15:103-112.
47. Reuben A, Tillman H, Fontana RJ, et al. Outcomes in adults with acute liver failure (ALF) from 1998-2013: an observational cohort study. Ann Intern Med. 2016;164:724-732.
48. Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14:1199-1206.
49. Bernal W, Donnelly MC, Durkalski-Mauldin VL, Simpson K, Wang Y, Wendon J. External validation of the USALFSG acute liver failure outcome prediction criteria. J Hepatol. 2017;66 (Suppl 1): S343-S344.
50. Kullak-Ublick G, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and assessment. Gut. 2017;66:1154-1164.
51. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci. 1991;36:1223-1228.
52. Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology. 2014;59:612-621.
53. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856-864.
54. Squires RH, Dhawan A, Alonso E, et al. Intravenous N-acetylcysteine in pediatric patients with non-acetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology. 2013;57:1542-1549.
55. Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl. 2008;14:25-30.
56. Hu J, Zhang Q, Ren Z, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in “non-acetaminophen” acute liver failure: a meta-analysis of prospective clinical trials. Clin Research Hepatol Gastroenterol. 2015;39:594-599.
57. Singh S, Hynan LS, Lee WM, The ALFSG. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013;58:1397-1402.
58. Stravitz RT, Sanyal AJ, Reisch J, et al. Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. Liver Int. 2013;33:1324-1331.